Compare BridgeBio Pharma Inc (BBIO) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? BridgeBio Pharma Inc trades at $82.08 (market cap $16.46B), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $30.92. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, iShares S&P GSCI Commodity-Indexed Trust ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | GSG | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $90.17 | $34.77 |
52-Week Low | $44.81 | $22.06 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
GSG trades at $30.52, up 3.6% with a bullish technical signal. Moving averages and oscillators support upward momentum, though the 6-day RSI indicates overbought conditions. Recent news highlights institutional shifts toward commodities, aligning with GSG's focus. Key support lies near $30, with resistance at $31.
The outlook remains positive amid commodity-driven market themes, but overbought technicals and reliance on macroeconomic trends pose risks. Upside depends on sustained commodity demand and institutional inflows, while volatility may test near-term support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
